Energy News / Shareholders Foundation, Inc.

NASDAQ:ACOR Shareholder Notice Lawsuit Alleges Misleading Statements by Acorda Therapeutics Inc

Via: ReleaseWire

Updated 1:09 PM CST, Mon, December 11,2017

A lawsuit was filed on behalf of investors in Acorda Therapeutics Inc (NASDAQ:ACOR) shares over alleged securities laws violations.

San Diego, CA -- (SBWIRE) -- 12/11/2017 -- The Shareholders Foundation announces that an investor, who purchased NASDAQ:ACOR shares, filed a lawsuit against Acorda Therapeutics.

Investors who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have certain options and for certain investors are short and strict deadlines running. Deadline: January 17, 2018. NASDAQ:ACOR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Acorda Therapeutics Inc (NASDAQ:ACOR) common shares between April 18, 2016, and November 14, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 18, 2016, and November 14, 2017, the Defendants made false and/or misleading statements and/or failed to disclose that tozadenant entailed significant undisclosed safety risks, that accordingly, the Company had overstated tozadenant's approval prospects and commercial viability, that for the foregoing reasons, the Company had likewise overstated the benefits of the Biotie Acquisition, and that as a result of the foregoing, Acorda's shares traded at artificially inflated prices between April 18, 2016, and November 14, 2017, and class members suffered significant losses and damages.

Those who purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqacor-shareholder-notice-lawsuit-alleges-misleading-statements-by-acorda-therapeutics-inc-902539.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com